TearLab (TEAR) Stock Price, News & Analysis

Company Overview

TearLab Corporation (OTCMKTS:TEAR) is a medical diagnostics company focused on advancing ocular health through innovative tear osmolarity testing. The company develops and commercializes point-of-care systems that measure tear osmolarity—a key biomarker for diagnosing and managing dry eye disease. By leveraging microfluidics and lab-quality analytical methods in a compact desktop platform, TearLab aims to bring objective, quantitative tear analysis to eye care practices worldwide.

Since its founding in 2004, TearLab has introduced the TearLab Osmolarity System and single-use Test Cards, which enable clinicians to obtain accurate osmolarity measurements in under thirty seconds using only a nanoliter tear sample. The system has received regulatory clearances in the United States, Europe and other international jurisdictions, and supports evidence-based treatment decisions in ophthalmology and optometry. TearLab continues to invest in research and development, collaborating with academic institutions and industry partners to refine measurement technology and explore additional tear-based biomarkers.

Headquartered in San Diego, California, TearLab serves a global customer base through direct sales and a network of distributors covering North America, Europe, Asia Pacific and Latin America. The company’s solutions are employed in a variety of clinical settings, including private eye care practices, hospital ophthalmology departments and dry eye research centers. TearLab’s leadership team is led by President and CEO John Tucker, whose background in medical device commercialization and diagnostics has guided the company through product launches, regulatory milestones and expansion of its global footprint.

Key Stats

• Today's Range: $0.06 to $0.06
• 50-Day Range: $0.06 to $0.06
• 52-Week Range: $0.02 to $0.22
• Volume: 20,200 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TEAR Stock Analysis - Frequently Asked Questions

How have TEAR shares performed this year?

TearLab's stock was trading at $0.0579 at the beginning of 2025. Since then, TEAR stock has increased by 0.0% and is now trading at $0.0579.

How were TearLab's earnings last quarter?

TearLab Corporation (OTCMKTS:TEAR) issued its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($0.10) EPS for the quarter. The medical research company had revenue of $5.85 million for the quarter.

When did TearLab's stock split?

TearLab shares reverse split before market open on Friday, February 24th 2017.The 1-10 reverse split was announced on Friday, February 24th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 23rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of TearLab?

Shares of TEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TearLab own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TearLab investors own include Vertex Energy (VTNR), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), CorMedix (CRMD) and Rigel Pharmaceuticals (RIGL).

Company Calendar

• Last Earnings: 8/08/2019
• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:TEAR
• Previous Symbol: NASDAQ:TEAR
• CIK: 1299139
• Web: www.tearlab.com
• Phone: 858-455-6006
• Fax: 858-812-0540
• Employees: 34
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A